VTX-2337 was proven to be safe and well tolerated with a predictable pharmacokinetic profile in 33 patients. In addition, VTX-2337 showed dose-dependent pharmacologic activity, according to the study results presented at the International Society for Biological Therapy of Cancer (ISBTC).
The preclinical results indicate the combination of VTX-2337 and Doxil elicits potent immune responses in an ovarian cancer model and that further clinical testing is warranted.
Preclinical evaluation of VTX-2337 suggested that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology.
VentiRx plans to initiate a Phase 1b/2a trial in the near future.
VentiRx co-founder and chief medical officer Robert Hershberg said that when used in conjunction with chemotherapy, compounds like VTX-2337 have the potential to change the way we’ve traditionally approached difficult-to-treat cancers.